MEDTRONIC KAPPA 700/600 SERIES PULSE GENERATORS AND MODEL 9953 SOFTWARE
Medtronic, Inc. · Decision date Jan 29, 1999
What did the FDA approve?
FDA approved Medtronic's Kappa 700/600 Series pacemakers on January 29, 1999, under PMA P980035. The approval covers the KDR 701, 703, 706, 721, 731, 733, 601, 603, and 606; KD 701, 703, and 706; KVDD 701; and KSR 701, 703, and 706 implantable pulse generators, along with Medtronic Vision Model 9953E software.
The statement lists indications for rate adaptive pacing, chronic cardiac pacing conditions such as second- or third-degree AV block and sinus node dysfunction, dual chamber and atrial tracking modes, and VDD modes. The source text reports these as the stated indications; it does not provide independent evidence of safety or clinical effectiveness. No supplement type or reason is recorded, so the database entry does not indicate whether this decision modifies a prior approval.
FDA approval order statement
Approval for the Medtronic.Kappa(TM) 700/600 Series Pacemakers, which include; Medtronic.Kappa(TM) Kdr 701, 703, 706, 721, 731, 733, 601, 603, and 606; Kd 701, 703, and 706; Kvdd 701; and Ksr 701, 703, and 706 implantable pacemakers with Medtronic.Vision (Model 9953E) Software. These devices are indicated for the following: Rate adaptive pacing in patients who may benefit from increase pacing rates concurrent with increases in activity; Accepted patient conditions warranting chronic cardiac pacing which include: - Symptomatic parosysmal or permanents second or third-degree AV block; - Symptomatic bilateral bundle branch block; - Symptomatic paroxysmal or transient sinus node dysfunctions with or without assocated AV conduction disorders; - Bradycardia-tachycardia syndrome to prevent symptomatic bradycardia or some forms of symptomatic tachyarrhythmias; - Vasovagal syndromes or hypersensitive carotid sinus syndromes. In addition, Medtronic.Kappa(TM) 700/600 Series pacemakers are also indicated for dual chamber and atrial tracking modes in patients who may benefit from maintenance of AV synchrony. Dual chamber modes are specifically indicated for treatment of conduction disorders that require restoration of both rate and AV synchrony, which include: -various degrees of AV block to maintain the atrial contribution to cardiac output; -VVI intolerance (e.g., pacemaker syndrome) in the presence of persistent sinus rhythm. Medtronic.Kappa(TM) 700/600 Series pacemakers are also indicated for VDD modes in patients having adequate atrial rates and the following indications: - Requirements for ventricular pacing when adequate atrial rates and adequate intracavitary atrial complexes are present. This includes the presence of complete AV block when atrial contribution is needed for hemodynamic benefit or when pacemaker syndrome has existed or is anticipated. Normal sinus rhythm and normal AV conduction in patients needing ventricular pacing intermittently.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Jan 29, 1999
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P980035
- Regulatory pathway
- Premarket approval application
- Applicant
- Medtronic, Inc.
- Product code
- NVZ
- Decision code
- APPR
- Decision date
- Jan 29, 1999
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Pulse generator, permanent, implantable.
- Applicant
- Medtronic, Inc.
- Product code
- NVZ
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P980035 received
Application receipt date recorded by FDA.
P980035 · FDA decision
APPR
P980035/S847 · Related supplement
Astra S DR MRI IPG, Astra S SR MRI IPG, Astra XT SR MRI IPG, Azure S DR MRI IPG, Azure S SR MRI IPG, Azure XT DR MRI IPG
P980035/S848 · Related supplement
Astra S DR MRI IPG (X3DR01); Astra S SR MRI IPG (X3SR01); Astra XT DR MRI IPG (X1DR01); Astra XT SR MRI IPG (X1SR01); Az
P980035/S849 · Related supplement
Astra S DR MRI IPG; Astra S SR MRI IPG; Astra XT DR MRI IPG; Astra XT SR MRI IPG; Azure S DR MRI IPG; Azure S SR MRI IPG
Timeline entries are records held by MedtechLedger for P980035. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P980035
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA supplement | Oct 5, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 23, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 29, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 8200 Coral Sea St. N.E, Ms Mvs11, Mounds View, MN, 55112
Sources and methodology
- Original FDA record: P980035
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

